Abbott announces data showing FreeStyle Libre reduces HbA1c levels
Abbott announced new data showing use of its FreeStyle Libre system, the company's continuous glucose monitoring technology, significantly reduced hemoglobin A1c levels for people living with Type 2 diabetes on intensive insulin therapy. The results were analyzed from retrospective, real-world data in three countries across Europe and presented as a late-breaker at the American Diabetes Association 79th Scientific Sessions in San Francisco. The goal of the combined analysis of three individual studies was to determine the impact of using the FreeStyle Libre system on glycemic control in people on intensive insulin therapy living with Type 2 diabetes, the most common form of diabetes where the body is unable to make enough insulin to keep blood glucose levels normal. Researchers evaluated de-identified records of 363 individuals across France, Germany and Austria, assessing their HbA1c levels over three to six months in people averaging about 63 years in age who use insulin multiple times a day for an average of more than eight years. The results showed lower HbA1c levels with the use of Abbott's technology after at least three months of use. The nearly 1% drop in HbA1c represents a significant reduction of glucose levels toward the ADA's recommended A1c goal of 7% for adults with diabetes.